Abstract
Reynolds and Strachan propose that routine home blood glucose monitoring (HBGM) not be used to monitor non-insulin treated patients with type 2 diabetes due to lack of evidence of its benefit. Their underlying concerns are that unnecessary HBGM will result in unjustified costs and that it may adversely affect patients' quality of life. They also suggest that large randomized trials be performed to provide guidance on the optimal use of HBGM in this population. The effectiveness of any glucose monitoring program is highly dependent on the ability …

This publication has 4 references indexed in Scilit: